Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 189 across all filing types
Latest filing 2025-05-08 Regulatory Filings
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F2 “Certification of Interim Filings” under Canadian NI 52-109. It is not the full interim report itself (IR) but a standalone regulatory certificate confirming interim MD&A and financial statements. It does not fit other specific categories (e.g., audit report, earnings release) and thus falls under miscellaneous regulatory filings. Therefore, it is best classified as a Regulatory Filing (RNS).
2025-05-08 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a statutory “Form 52-109F2 Certification of Interim Filings” by the CFO, referencing review and controls over the interim financial report and MD&A for the quarter ended March 31, 2025. It is not the interim report itself (IR), nor an annual report (10-K), audit report (AR), MD&A (MDA), or any of the other specific categories (e.g., dividends, share issues). Instead, it is a regulatory filing—an officer’s certification—required under securities legislation that does not fit the specialized labels, so it falls into the fallback category of Regulatory Filings (RNS).
2025-05-08 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is clearly labeled as “MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2025” and contains forward-looking statements, non-IFRS measure reconciliations, and a detailed narrative of business segments and performance. There are no standalone financial statements or signatures as in a full interim report, and it is much more than a brief earnings release. This matches the “Management Reports (Code: MDA)” definition, which covers management’s detailed explanation of financial results, business trends, and outlook.
2025-05-08 English
Interim financial statements/report – English.pdf
Audit Report / Information Classification · 1% confidence The document is a CFO’s certificate under NI 52-109 attesting to the interim financial report and management discussion & analysis for the quarter ended March 31, 2025, focusing on internal controls and accuracy of disclosures. It is not the full interim report but a standalone attestation of internal control and applied accounting principles, which falls under Audit Report/Information (AR). Q1 2025
2025-05-08 French
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for HLS Therapeutics Inc. for the three months ended March 31, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss, Statement of Comprehensive Loss, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows) along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q1 2025
2025-05-08 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release announcing HLS Therapeutics’ first quarter 2025 financial results, including revenue, EBITDA, net loss, operational highlights, and a conference call notification. It contains key quarterly financial metrics and commentary, but is not a full MD&A or transcript. This matches the definition of an Earnings Release. Q1 2025
2025-05-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.